Mona K Tawfik1, Seham A Helmy2, Dahlia I Badran3, Sawsan A Zaitone4. 1. Department of Pharmacology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt. 2. Department of Cytology and Histology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt; Female Collage of Applied Medical Sciences, Bisha University, Bisha, Saudi Arabia. 3. Department of Biochemistry, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt. 4. Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt. Electronic address: sawsan_zaytoon@pharm.suez.edu.eg.
Abstract
AIMS: Painful diabetic neuropathy (PDN) is one of the most frequent complications of diabetes and the current therapies have limited efficacy. This study aimed to study the neuroprotective effect of duloxetine, a serotonin noradrenaline reuptake inhibitor (SNRI), in a mouse model of diabetic neuropathy. MAIN METHODS: Nine weeks after developing of PDN, mice were treated with either saline or duloxetine (15 or 30 mg/kg) for four weeks. The effect of duloxetine was assessed in terms of pain responses, histopathology of sciatic nerve and spinal cord, sciatic nerve growth factor (NGF) gene expression and on the spinal expression of astrocytes (glial fibrillary acidic protein, GFAP) and microglia (CD11b). KEY FINDINGS: The present results highlighted that duloxetine (30 mg/kg) increased the withdrawal threshold in von-Frey test. In addition, both doses of duloxetine prolonged the licking time and latency to jump in the hot-plate test. Moreover, duloxetine administration downregulated the spinal expression of both CD11b and GFAP associated with enhancement in sciatic mRNA expression of NGF. SIGNIFICANCE: The current results highlighted that duloxetine provided peripheral and central neuroprotective effects in neuropathic pain is, at least in part, related to its downregulation in spinal astrocytes and microglia. Further, this neuroprotective effect was accompanied by upregulation of sciatic expression of NGF.
AIMS: Painful diabetic neuropathy (PDN) is one of the most frequent complications of diabetes and the current therapies have limited efficacy. This study aimed to study the neuroprotective effect of duloxetine, a serotonin noradrenaline reuptake inhibitor (SNRI), in a mouse model of diabetic neuropathy. MAIN METHODS: Nine weeks after developing of PDN, mice were treated with either saline or duloxetine (15 or 30 mg/kg) for four weeks. The effect of duloxetine was assessed in terms of pain responses, histopathology of sciatic nerve and spinal cord, sciatic nerve growth factor (NGF) gene expression and on the spinal expression of astrocytes (glial fibrillary acidic protein, GFAP) and microglia (CD11b). KEY FINDINGS: The present results highlighted that duloxetine (30 mg/kg) increased the withdrawal threshold in von-Frey test. In addition, both doses of duloxetine prolonged the licking time and latency to jump in the hot-plate test. Moreover, duloxetine administration downregulated the spinal expression of both CD11b and GFAP associated with enhancement in sciatic mRNA expression of NGF. SIGNIFICANCE: The current results highlighted that duloxetine provided peripheral and central neuroprotective effects in neuropathic pain is, at least in part, related to its downregulation in spinal astrocytes and microglia. Further, this neuroprotective effect was accompanied by upregulation of sciatic expression of NGF.
Authors: Patricia A Lozano; Ahmed B Alarabi; Sarah E Garcia; Erica T Boakye; Hendreta T Kingbong; Elie Naddour; Daniel Villalobos-García; Precious Badejo; Medhat S El-Halawany; Fadi T Khasawneh; Fatima Z Alshbool Journal: Int J Mol Sci Date: 2022-02-26 Impact factor: 5.923
Authors: Mohamed El-Sherbiny; Rehab M El-Sayed; Mohamed A Helal; Afaf T Ibrahiem; Hoda S Elmahdi; Mohamed Ahmed Eladl; Shymaa E Bilay; Asma M Alshahrani; Mona K Tawfik; Ziad E Hamed; Amany O Mohamed; Sawsan A Zaitone Journal: Molecules Date: 2021-11-13 Impact factor: 4.411
Authors: Jie Quan; Jin Young Lee; Hoon Choi; Young Chan Kim; Sungwon Yang; Jongmin Jeong; Hue Jung Park Journal: Pharmaceutics Date: 2022-03-18 Impact factor: 6.321